Effects of sulfonylureas on tumor growth: a review of the literature.
暂无分享,去创建一个
[1] C. Mantzoros,et al. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. , 2013, Metabolism: clinical and experimental.
[2] S. Gandini,et al. Metformin and breast cancer risk. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Habib,et al. Diabetes and Risk of Cancer , 2013, ISRN oncology.
[4] F. Sung,et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients , 2013, International journal of cancer.
[5] Mariel Núñez,et al. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231 , 2013, BMC Pharmacology and Toxicology.
[6] M Smans,et al. Diabetes and breast cancer risk: a meta-analysis , 2012, British Journal of Cancer.
[7] A. Thompson,et al. Diabetes, metformin, and breast cancer: lilac time? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Chantal,et al. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. , 2012, Diabetes research and clinical practice.
[9] Xu-hui Zhang,et al. Increased risk of cancer in patients with type 2 diabetes mellitus: A retrospective cohort study in China , 2012, BMC Public Health.
[10] A. Luini,et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Manson,et al. Diabetes, metformin, and breast cancer in postmenopausal women. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. la Vecchia,et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. , 2012, The oncologist.
[13] Kazuo Umezawa,et al. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet‐derived growth factor in ovarian clear cell carcinoma ES‐2 cells , 2012, FEBS letters.
[14] C. Ra,et al. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: Role for ATP-sensitive K+ channels and endoplasmic reticulum stress , 2012, International journal of oncology.
[15] R. Marais,et al. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Hsiao,et al. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. , 2012, Metabolism: clinical and experimental.
[17] A. Śliwińska,et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells , 2011, Molecular Biology Reports.
[18] E. Platz,et al. A Prospective Study of the Associations Between Treated Diabetes and Cancer Outcomes , 2011, Diabetes Care.
[19] H. Hense,et al. Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort , 2011, Diabetology & metabolic syndrome.
[20] M. Noda,et al. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[21] R. Ozaki,et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. , 2010, Diabetes research and clinical practice.
[22] H. Sørensen,et al. Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case–Control Study in Denmark , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[23] T. Sasazuki,et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. , 2010, Journal of diabetes and its complications.
[24] A. Śliwińska,et al. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. , 2010, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[25] A. Szewczyk,et al. Pharmacology of mitochondrial potassium channels: dark side of the field , 2010, FEBS letters.
[26] S. Krähenbühl,et al. Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer , 2010, Diabetes Care.
[27] J. Bryan,et al. Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress. , 2009, The Journal of clinical investigation.
[28] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Goodwin,et al. Metformin in breast cancer: time for action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Gale,et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.
[31] D. Balzi,et al. Sulphonylureas and cancer: a case–control study , 2008, Acta Diabetologica.
[32] Gang Hu,et al. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. , 2008, Biochemical pharmacology.
[33] Jing Yi,et al. Cancer cell killing via ROS: To increase or decrease, that is the question , 2008, Cancer biology & therapy.
[34] M. Pollak,et al. Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.
[35] R. Takayanagi,et al. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. , 2008, Metabolism: clinical and experimental.
[36] J. Błasiak,et al. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). , 2008, Chemico-biological interactions.
[37] M. Ihnat,et al. Evaluation of gliclazide ability to attenuate the hyperglycaemic ‘memory’ induced by high glucose in isolated human endothelial cells , 2008, Diabetes/metabolism research and reviews.
[38] T. Kurtz,et al. Type 2 diabetes and oral antihyperglycemic drugs. , 2008, Current medicinal chemistry.
[39] Dong Chang,et al. Oxidative damage to DNA and its relationship with diabetic complications. , 2007, Biomedical and environmental sciences : BES.
[40] Pang Xiaoyu,et al. Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell. , 2007, Gynecologic oncology.
[41] A. Pappo,et al. A phase I study of sulofenur in refractory pediatric malignant solid tumors , 2007, Investigational New Drugs.
[42] Sébastien Bonnet,et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.
[43] J. Błasiak,et al. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. , 2006, Chemico-biological interactions.
[44] P. Schumacker,et al. Reactive oxygen species in cancer cells: live by the sword, die by the sword. , 2006, Cancer cell.
[45] S. Majumdar,et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. , 2006, Diabetes care.
[46] Antonio Felipe,et al. Potassium channels: new targets in cancer therapy. , 2006, Cancer detection and prevention.
[47] F. Ashcroft. ATP-sensitive potassium channelopathies: focus on insulin secretion. , 2005, The Journal of clinical investigation.
[48] B. O’Rourke,et al. Mitochondrial K(ATP) channels in cell survival and death. , 2005, Journal of molecular and cellular cardiology.
[49] W. Kunz,et al. Characterization of superoxide production sites in isolated rat brain and skeletal muscle mitochondria. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[50] Dario R Alessi,et al. Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.
[51] J. Samet,et al. Fasting serum glucose level and cancer risk in Korean men and women. , 2005, JAMA.
[52] H. Choi,et al. Novel diarylsulfonylurea derivatives as potent antimitotic agents. , 2004, Bioorganic & medicinal chemistry letters.
[53] M. Conti. Targeting K+ channels for cancer therapy. , 2004, Journal of experimental therapeutics & oncology.
[54] P. Houghton,et al. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise , 2004, Investigational New Drugs.
[55] C. Takimoto,et al. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] T. Kizaki,et al. Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide , 2003 .
[57] H. Kwan,et al. Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells. , 2003, International journal of molecular medicine.
[58] Mansoor Abdul,et al. Expression and activity of potassium ion channels in human prostate cancer. , 2002, Cancer letters.
[59] A. Ghiselli,et al. Gliclazide improves anti‐oxidant status and nitric oxide‐mediated vasodilation in Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[60] Mansoor Abdul,et al. Voltage-gated potassium ion channels in colon cancer. , 2002, Oncology reports.
[61] Baofeng Yang,et al. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. , 2002, Cancer research.
[62] R. Fine,et al. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. , 2002, Biochemical pharmacology.
[63] N. Hoosein,et al. Voltage-gated sodium ion channels in prostate cancer: expression and activity. , 2002, Anticancer research.
[64] J. Kim,et al. Induction of G(2)/M phase arrest and apoptosis by a new synthetic anti-cancer agent, DW2282, in promyelocytic leukemia (HL-60) cells. , 2001, Biochemical pharmacology.
[65] O. Fardel,et al. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells , 2001, British journal of pharmacology.
[66] D. Spray,et al. KATP Channels Regulate Mitogenically Induced Proliferation in Primary Rat Hepatocytes and Human Liver Cell Lines , 2000, The Journal of Biological Chemistry.
[67] R. O’Brien,et al. In vitro and in vivo antioxidant properties of gliclazide. , 2000, Journal of diabetes and its complications.
[68] P. Meier,et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. , 2000, Gastroenterology.
[69] L. Packer,et al. Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study. , 2000, Metabolism: clinical and experimental.
[70] E. Moon,et al. Characterization of the anticancer activity of DW2282, a new anticancer agent. , 1999, Anticancer research.
[71] B. Masereel,et al. P-glycoprotein inhibition by glibenclamide and related compounds , 1999, Pflügers Archiv.
[72] D. V. Von Hoff,et al. Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. , 1999, Anti-cancer drugs.
[73] J. Suttles,et al. Membrane Potassium Channels and Human Bladder Tumor Cells: II. Growth Properties , 1998, The Journal of Membrane Biology.
[74] A Rubartelli,et al. Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. , 1997, Blood.
[75] D. Sheppard,et al. Mechanism of Glibenclamide Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channels Expressed in a Murine Cell Line , 1997, The Journal of physiology.
[76] S. Cole,et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.
[77] W. Wonderlin,et al. Inhibition of ATP‐sensitive potassium channels causes reversible cell‐cycle arrest of human breast cancer cells in tissue culture , 1995, Journal of cellular physiology.
[78] R. Schultz,et al. Effect of albumin on antitumor activity of diarylsulfonylureas. , 1993, Anticancer research.
[79] D. Alberts,et al. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. , 1992, Journal of the National Cancer Institute.
[80] F. Mohamadi,et al. Sulfonylureas: a new class of cancer chemotherapeutic agents. , 1992, Journal of medicinal chemistry.
[81] J. Howbert,et al. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984. , 1992, The Journal of urology.
[82] P. Houghton,et al. Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions. , 1991, Cancer research.
[83] R. W. Harper,et al. Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. , 1990, Journal of medicinal chemistry.
[84] Grindey Gb. Current status of cancer drug development: failure or limited success? , 1990 .
[85] J. Howbert,et al. Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells. , 1990, Cancer research.
[86] G. Grindey. Current status of cancer drug development: failure or limited success? , 1990, Cancer cells.
[87] M. Holdsworth,et al. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] H. Grosse. [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.